Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, sending shares higher in pre-market trading. Concurrently, Merck & Co. (MRK) lowered its sales outlook despite topping third quarter estimates, sending the stock lower.
Julie Hyman and Brad Smith report more on these two pharma companies’ earnings results tied to some of their top-selling drugs.
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
This post was written by Luke Carberry Mogan.
Visited 1 times, 1 visit(s) today
